Not available
Quote | Celldex Therapeutics Inc. (NASDAQ:CLDX)
Last: | $38.85 |
---|---|
Change Percent: | -1.37% |
Open: | $38.5 |
Close: | $38.85 |
High: | $39.41 |
Low: | $37.99 |
Volume: | 552,455 |
Last Trade Date Time: | 04/22/2024 03:00:00 am |
News | Celldex Therapeutics Inc. (NASDAQ:CLDX)
2024-04-20 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CInd...
Message Board Posts | Celldex Therapeutics Inc. (NASDAQ:CLDX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CLDX News Article - Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & In | whytestocks | investorshangout | 03/29/2023 6:50:56 PM |
COULD BE. | fwb | investorshub | 03/01/2023 8:40:33 PM |
Could be a buyout coming | harry crumb | investorshub | 03/01/2023 4:23:23 PM |
Another positive for cldx $$$$ | harry crumb | investorshub | 02/27/2023 12:24:53 PM |
This stock use to be called Avant Immunotherapeutics | fwb | investorshub | 02/07/2023 9:02:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
2024-04-20 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CInd...
2024-04-10 12:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...